BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35435366)

  • 1. Concordance of HER2 status tested by IHC and FISH in biopsy and surgical resection specimens and comparison with clinicopathological features in gastric carcinoma.
    Nergiz D; Alikanoğlu AS; Süren D; Gömceli İ; Öztürk B
    Indian J Pathol Microbiol; 2022; 65(2):321-327. PubMed ID: 35435366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
    Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
    Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens.
    Fazlollahi L; Remotti HE; Iuga A; Yang HM; Lagana SM; Sepulveda AR
    Arch Pathol Lab Med; 2018 Apr; 142(4):516-522. PubMed ID: 28782986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.
    Kanayama K; Imai H; Yoneda M; Hirokawa YS; Shiraishi T
    Cancer Sci; 2016 Apr; 107(4):536-42. PubMed ID: 26752196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human epidermal growth factor receptor 2 amplification detection by droplet digital polymerase chain reaction in formalin-fixed paraffin-embedded breast and gastric cancer samples.
    Wang X; Wu Y; Song X; Sun C; Wu C; Feng H
    J Cancer Res Ther; 2017; 13(4):730-734. PubMed ID: 28901323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.
    Yano T; Doi T; Ohtsu A; Boku N; Hashizume K; Nakanishi M; Ochiai A
    Oncol Rep; 2006 Jan; 15(1):65-71. PubMed ID: 16328035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
    Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
    J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
    Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
    Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
    Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
    Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Image cytometric HER2 in gastric carcinoma: is a new algorithm needed?
    Ormenisan C; Wang J; Lawson D; Cohen C
    Appl Immunohistochem Mol Morphol; 2013 Oct; 21(5):414-9. PubMed ID: 23197004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance.
    Huang SC; Ng KF; Lee SE; Chen KH; Yeh TS; Chen TC
    Gastric Cancer; 2016 Jan; 19(1):176-82. PubMed ID: 25512144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens.
    Tsuda H; Kurosumi M; Umemura S; Yamamoto S; Kobayashi T; Osamura RY
    BMC Cancer; 2010 Oct; 10():534. PubMed ID: 20925963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens.
    Ahn S; Ahn S; Van Vrancken M; Lee M; Ha SY; Lee H; Min BH; Lee JH; Kim JJ; Choi S; Jung SH; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Kim KM
    Oncotarget; 2015 Nov; 6(35):38372-80. PubMed ID: 26460823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
    Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
    Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Could quantitative real-time polymerase chain reaction assay serve as an alternative test method to evaluate human epidermal growth factor receptor 2 status of gastric carcinoma in the South Asian setting?
    Kannangara DKS; Lokuhetty MDS; Subasinghe D; Gunawardene YINS; Dassanayake RS
    Indian J Gastroenterol; 2019 Aug; 38(4):317-324. PubMed ID: 31401730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
    Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
    Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concordance of HER2 Immunohistochemistry and Fluorescence
    Furrer D; Jacob S; Caron C; Sanschagrin F; Provencher L; Diorio C
    Anticancer Res; 2017 Jun; 37(6):3323-3329. PubMed ID: 28551685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen Method.
    Chao WR; Lee MY; Ruan A; Sheng HP; Hsu JD; Han CP; Koo CL
    PLoS One; 2015; 10(11):e0142135. PubMed ID: 26566289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.